Quinupristin-dalfopristin and linezolid: Evidence and opinion

Clinical Infectious Diseases

Volumn 36, Issue 4, 2003, Pages 473-481

  Eliopoulos, George M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DEXTROMETHORPHAN; DICLOXACILLIN; LINEZOLID; METICILLIN; OXACILLIN; RNA 23S; SEROTONIN UPTAKE INHIBITOR; VANCOMYCIN;

AGITATION; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ERADICATION THERAPY; FEVER; HEADACHE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; OSTEOMYELITIS; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 0037442373     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367662     Document Type: Review

References (101)

1. Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31:437-51.
2. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43:75-83.
3. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8.
4. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
5. Cocito C, DiGiambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997; 39(Suppl A):7-13.
6. Allignet J, El Solh N. Characterization of a new staphylococcal gene, vgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. Gene 1997; 202:133-8.
7. Thal LA, Zervos MJ. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. J Antimicrob Chemother 1999; 43:171-6.
8. Malbruny B, Canu A, Bozdogan, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:2200-7.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
10. Barrett MS, Jones RN. In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species. Diagn Microbiol Infect Dis 1996; 25:147-9.
11. Mathai D, Lewis MT, Kugler KC, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I. Results from the SENTRY antimicrobial surveillance program (North America, 1998). Diagn Microbiol Infect Dis 2001; 39:105-16.
12. von Eiff C, Reinert RR, Kresken M, et al. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. J Clin Microbiol 2000; 38:2819-23.
13. Lewis MT, Gales AC, Sader HS, et al. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). Diagn Microbiol Infect Dis 2000; 37:63-74.
14. Chang SC, Fang CT, Hsueh PR, et al. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan. Diagn Microbiol Infect Dis 1999; 33:299-303.
15. Andrews J, Ashby J, Jevons G, Lines N, Wise R. Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997. J Antimicrob Chemother 1999; 43:689-98.
16. Schmitz FJ, Sadurski R, Stattfeld A, et al. Cross resistance analyses and molecular typing of Staphylococcus aureus and Streptococcus spp isolates resistant to quinupristin/dalfopristin. J Antimicrob Chemother 1999; 44:847-55.
17. Henwood CJ, Livermore DM, Johnson AP, et al. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46:931-40.
18. Mutnick AH, Biedenbach DJ, Turndige JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002; 43:65-73.
19. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. J Antimicrob Chemother 1999; 43:783-92.
20. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity, to glycopeptides. J Clin Microbiol 2001; 39:3586-90.
21. Cohen MA, Huband MD. Activity of clinafloxacin; trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 1999; 33:43-6.
22. Gordon KA, Beach ML, Biedenbach DJ, et al. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002; 43:157-62.
23. Wisplinghoff H, Reinert RR, Cornely O, Seifert H. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol 1999; 37:1876-80.
24. Reinert RR, vonEiff C, Kresken M, et al. Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin/dalfopristin and eight other antimicrobials. J Clin Microbiol 2001; 39:1928-31.
25. Kugler KC, Denys GA, Wilson ML, Jones RN. Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2000; 36:269-72.
26. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845-50.
27. Eliopoulos GM, Wennersten CB, Gold HS, et al. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother 1998; 42:1088-92.
28. Luh KT, Hsueh PR, Teng LJ, et al. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44:3374-80.
29. Werner G, Klare I, Witte W. Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur J Clin Microbiol Infect Dis 1998; 17:401-2.
30. Simjee S, McDermott PF, Wagner DD, White DG. Variation within the vat(E) allele of Enterococcus faecium isolates from retail poultry samples. Antimicrob Agents Chemother 2001; 45:2931-2.
31. Hayes JR, McIntosh AC, Qaiyumi S, et al. High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment. J Clin Microbiol 2001; 39:2298-9.
32. McDonald LC, Rossiter S, Mackinson C, et al. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 2001; 345:1155-60.
33. Johnson CC, Slavoski L, Schwartz M, et al. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 1995; 21:169-73.
34. Peric M, Lin G, Clark CL, et al. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents. J Antimicrob Chemother 2002; 50:95-100.
35. Caron F, Gold HS, Wennersten CB, et al. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41:2749-53.
36. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467-70.
37. Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 2000; 44:2880-2.
38. Carbon C. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. J Antimicrob Chemother 1997; 39(Suppl A):115-9.
39. Batard E, Jacqueline C, Boutoille D, et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother 2002; 46:2174-8.
40. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000; 46:775-84.
41. Batts DH, Lavin BS, Eliopoulos GM. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy - a status report. Curr Clin Top Infect Dis 2001; 21:227-51.
42. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000; 30:790-7.
43. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44:251-61.
44. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33:1816-23.
45. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin. J Antimicrob Chemother 1999; 44:263-73.
46. Fagon JY, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia, prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161:753-62.
47. Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001; 47:105-8.
48. Dowzicky M, Talbot GH, Feger C, et al. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during the worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37:57-62.
49. Chow JW, Davidson A, Sanford E, Zervos MJ. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997; 24:91-2.
50. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44(Suppl A):37-46.
51. Tan TY, Pitman I, Penrose-Stevens A, et al. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J Infect 2000; 41:95-7.
52. Williamson JC, Glazier SS, Peacock IE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002; 104:54-6.
53. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001; 45:3202-4.
54. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83-6.
55. Cole RP, Roberts WD, Cheng MD. Hyponatremia associated with quinupristin-dalfopristin. Ann Intern Med 2000; 133:485.
56. Launay O, Chemlal K, Andrieu V, Carbon C. Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy. Clin Infect Dis 1997; 25:156.
57. Rehm SJ, Graham DR, Srinath L, et al. Successful administration of quinupristin/dalfopristin in the outpatient setting. J Antimicrob Chemother 2001; 47:639-45.
58. Aoki H, Ke L, Poppe SM, et al. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002; 46:1080-5.
59. Champney WS, Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 2002; 44:350-6.
60. Fines M, Leclercq R. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45:797-802.
61. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.
62. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002; 42:137-9.
63. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.
64. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867-9.
65. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
66. Cercenado E, García-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J Antimicrob Chemother 2001; 47:77-81.
67. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996; 40:1745-7.
68. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12.
69. Schaadt RD, Batts DH, Daley-Yates PT, et al. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn Microbiol Infect Dis 1997; 28:201-4.
70. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-13.
71. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
72. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
73. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol 2002; 33:221-3.
74. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002; 34:1412-4.
75. Bassetti M, DiBiagio A, Cenderello G, et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA) J Infect 2001; 43:148-57.
76. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30:146-51.
77. Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32:1373-5.
78. McNeil SA, Clarke NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clin Infect Dis 2000; 30:403-4.
79. Moise PA, Birmingham MC, Forrest A, Schentag JJ. Linezolid use in patients who are intolerant to or fail vancomycin [abstract 2233]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
80. Dresser LD, Birmingham MC, Karchmer AW, et al. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
81. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73-7.
82. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001; 20:432-4.
83. Steinmetz MP, Vogelbaum MA, DeGeorgia MA, et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001; 29:2383-5.
84. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477-82.
85. Sperber SJ, Levine JF, Gross PA. Low serum linezolid levels in a patient with persistent MRSA bacteremia [abstract 465]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
86. Brown-Elliott BA, Wallace RJ Jr, Griffith DE, et al. Safety and tolerance of long-term therapy of linezolid for mycobacterial and nocardial disease with a focus on once daily therapy [abstract 609]. In: Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002.
87. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis 2002; 34:1651-2.
88. Hicks K, Hachem RY, Huen A, Raad II. Myelosuppression and serotonin syndrome associated with linezolid and selective serotonin re-uptake inhibitors (SSRIs) [abstract 467]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
89. 88A Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn, 2002.
90. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-6.
91. Orrick JJ, Johns T, Janelle J, Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis 2002; 35:348-9.
92. Attassi K, Hershberger E, Alam R, Zervos M. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-8.
93. Forrest A, Rayner CR, Meagher A, et al. Pharmacostatistical modelling of hematologic effects of linezolid in seriously ill patients [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
94. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001; 285:1291.
95. Abena PA, Mathieux VG, Scheiff JM, et al. Linezolid and reversible myelosuppression. JAMA 2001; 286:1973.
96. Green SL, Maddox JC. Linezolid and reversible myelosuppression. JAMA 2001; 286:1974.
97. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis 2002; 35:e29-31.
98. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002; 35:347-8.
99. Patron RL. Myelodisplasia and severe fatal pancytopenia associated with linezolid treatment [abstract 466]. In: Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
100. Sgarabotto D, Cusinato R, Narne E, et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococcal infections: evaluation of 5 cases. Scand J Infect Dis 2002; 34:122-6.
101. Moise-Broder PA, Forrest A, Jagodzinski LM, Schentag JJ. Methicillin-resistant Staphylococcus aureus bloodstream infections failing vancomycin (Vm): results of increasing Vm versus adding quinupristin-dalfopristin to Vm [abstract 182]. In: Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002.